Skip to main navigation Skip to search Skip to main content

Erratum: SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA (Nephrology Dialysis Transplantation (2019) (gfy407) DOI: 10.1093/NDT/gfy407)

  • Pantelis Sarafidis
  • , Charles J. Ferro
  • , Enrique Morales
  • , Alberto Ortiz
  • , Jolanta Malyszko
  • , Radovan Hojs
  • , Khaled Khazim
  • , Robert Ekart
  • , Jose Valdivielso
  • , Denis Fouque
  • , Gérard M. London
  • , Ziad Massy
  • , Petro Ruggenenti
  • , Esteban Porrini
  • , Andrzej Wiecek
  • , Carmine Zoccali
  • , Francesca Mallamaci
  • , Mads Hornum

Research output: Contribution to journalComment/debate

10 Scopus citations

Abstract

In the original article, the words 'micro- or microalbuminuria' should have read 'micro- or macroalbuminuria' in the top boxes of Figures 4 and 5.

Original languageEnglish
Pages (from-to)1825
Number of pages1
JournalNephrology Dialysis Transplantation
Volume35
Issue number10
DOIs
StatePublished - 1 Oct 2020

Bibliographical note

Publisher Copyright:
© 2020 Oxford University Press. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Erratum: SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA (Nephrology Dialysis Transplantation (2019) (gfy407) DOI: 10.1093/NDT/gfy407)'. Together they form a unique fingerprint.

Cite this